MedStar Authors catalog › Details for: Left Ventricular Hypertrophy Does Not Affect 1-Year Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement.
Normal view MARC view ISBD view

Left Ventricular Hypertrophy Does Not Affect 1-Year Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement.

by Thourani, Vinod H.
Citation: ; Jacc: Cardiovascular Interventions. 12(4):373-382, 2019 02 25..Journal: JACC. Cardiovascular interventions.Published: ; 2019; ISSN: 1936-8798.Full author list: Bhatt DL; Kaneko T; Kirtane AJ; Kosinski AS; Lowenstern A; Manandhar P; Mathew V; Shah B; Thourani VH; Varshney AS; Vemulapalli S.UI/PMID: 30784643.Subject(s): Aged | *Ventricular Remodeling | *Ventricular Function, Left | United States/ep [Epidemiology] | Treatment Outcome | *Transcatheter Aortic Valve Replacement | Transcatheter Aortic Valve Replacement/mo [Mortality] | Transcatheter Aortic Valve Replacement/ae [Adverse Effects] | Time Factors | Stroke/mo [Mortality] | Sex Factors | Severity of Illness Index | Risk Factors | Risk Assessment | Registries | Recovery of Function | Myocardial Infarction/mo [Mortality] | Male | *Hypertrophy, Left Ventricular/pp [Physiopathology] | Hypertrophy, Left Ventricular/mo [Mortality] | Hypertrophy, Left Ventricular/dg [Diagnostic Imaging] | Humans | Female | Databases, Factual | *Aortic Valve Stenosis/su [Surgery] | Aortic Valve Stenosis/pp [Physiopathology] | Aortic Valve Stenosis/mo [Mortality] | Aortic Valve Stenosis/dg [Diagnostic Imaging] | *Aortic Valve/su [Surgery] | Aortic Valve/pp [Physiopathology] | Aortic Valve/dg [Diagnostic Imaging] | Aged, 80 and overInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access online Digital Object Identifier: (Click here) Abbreviated citation: ; JACC Cardiovasc Interv. 12(4):373-382, 2019 02 25.Local Holdings: Available online through MWHC library: 2008 - present.Abstract: BACKGROUND: The association between pre-procedural LVH pattern and severity and clinical outcomes after TAVR is uncertain.Abstract: CONCLUSIONS: In a contemporary cohort of patients who underwent TAVR, pre-procedural LVH according to left ventricular mass index and relative wall thickness was not associated with adverse outcomes at 1-year follow-up. TAVR is likely to benefit patients with severe aortic stenosis regardless of the presence of LVH.Abstract: Copyright (c) 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.Abstract: METHODS: Patients (n = 31,199) across 422 sites who underwent TAVR from November 2011 through June 2016 as part of the Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapies) Registry linked with the Centers for Medicare and Medicaid Services database were evaluated by varying LVH patterns, according to sex-specific cutoffs for left ventricular mass index and relative wall thickness. The association between LVH pattern (concentric remodeling, concentric LVH, and eccentric LVH) and outcomes (rates of mortality, myocardial infarction [MI], stroke, new dialysis requirement) at 1-year follow-up were evaluated using multivariate hazard models.Abstract: OBJECTIVES: The aim of this study was to evaluate the association between pre-procedural left ventricular hypertrophy (LVH) patterns and clinical outcomes after transcatheter aortic valve replacement (TAVR).Abstract: RESULTS: There were no significant associations between concentric remodeling (death: adjusted hazard ratio [HR]: 1.03; 95% confidence interval [CI]: 0.93 to 1.15; MI: HR: 1.05; 95% CI: 0.76 to 1.46; stroke: HR: 1.11; 95% CI: 0.89 to 1.39; new dialysis: HR: 0.86; 95% CI: 0.64 to 1.15), concentric LVH (death: HR: 1.04; 95% CI: 0.95 to 1.15; MI: HR: 1.12; 95% CI: 0.82 to 1.52; stroke: HR: 1.14; 95% CI: 0.92 to 1.40; new dialysis: HR: 1.17; 95% CI: 0.90 to 1.52), or eccentric LVH (death: HR: 0.98; 95% CI: 0.87 to 1.10; MI: HR: 1.07; 95% CI: 0.71 to 1.63; stroke: HR: 1.01; 95% CI: 0.78 to 1.32; new dialysis: HR: 1.25; 95% CI: 0.92 to 1.70) and outcomes at 1 year compared with patients without LVH.

Powered by Koha